Making sense of Canada’s specialty pharmaceutical market
Making sense of Canada’s specialty pharmaceutical market
20Sense is a research and consulting firm that works with Canada’s specialty pharmaceutical stakeholders to optimize data, insights and programs that deliver better outcomes for patients and value for payers.
Outcomes-Based Agreements
20Sense collaborates with forward-thinking pharmaceutical stakeholders to define best practices for building and implementing effective outcome-based innovative market access agreements that support timely and equitable patient access to novel therapies.
Learn more about outcomes-based agreements
Patient Support Programs
20Sense collaborates with Canadian stakeholders to advance PSP capabilities, best practices and standards to best support positive outcomes and access for patients, with a focus on continuous process improvement and real-world data from PSPs.
Learn more about PSPs
The 20Sense Report
The specialty pharmaceutical industry in Canada is evolving at a rapid pace. Each quarter, The 20Sense Report explores these changes by investigating the topics and initiatives affecting all stakeholders.
Read The 20Sense Report
Our Team
Specialized therapies require a different way of thinking. 20Sense identifies opportunities for Canadian specialty pharmaceutical stakeholders to provide best-in-class solutions for patients.
Recent Publications
Report: Outcomes-Based Agreements in Canada
Interview: Dr. Michèle de Guise, President and General Manager of INESSS, on Value-Based Healthcare
Survey Results: Canadian OBA Experience and Perceptions